Pharmacology Watch – July 1, 2017
July 1, 2017
View Issues
-
Researchers Offer Remedies for FDA’s Accelerated Approval Program
Once a drug receives accelerated approved, manufacturers are free to charge whatever they believe the market will bear without evidence that the drug affects disease progression.
-
Investigators Conclude Long-term Opioid Use Increases Dependency and Overdose Risks
Nationwide epidemic has raised questions regarding the long-term use of such medication for chronic pain conditions.
-
Ohio Attorney General Files Suit Against 5 Pharmaceutical Companies Over Opioids
The suit alleges fraudulent marketing that misled the state, prescribers, and patients about the risks of these medications.
-
FDA Actions
In this section: FDA approves new amyotrophic lateral sclerosis, expands the indication for pembrolizumab, adds giant cell arteritis to the indication for tocilizumab, and green lights generic ADHD drug.